& AUC w/ strong CYP3A4 inhibitors eg, ketoconazole, clarithromycin, nefazodone, ritonavir, atazanavir; moderate CYP3A4 inhibitors eg, diltiazem, amprenavir, aprepitant, erythromycin, fluconazole; cyclosporine. Increased exposure w/ grapefruit juice; potent P-gp & moderate CYP3A4 inhibitors eg, verapamil, quinidine. Decreased Cmax
& AUC w/ CYP3A inducers eg, rifampicin. Decreased exposure w/ other CYP3A inducers eg, phenytoin, carbamazepine, phenobarb. Delayed & decreased exposure w/ morphine. Increased Cmax
& AUC of simvastatin, atorvastatin, digoxin. Increased exposure to CYP3A4 substrates w/ narrow therapeutic index eg, cisapride, ergot alkaloids. Increased risk of bleeding w/ SSRIs eg, paroxetine, sertraline, citalopram. Medicinal products altering haemostatis (eg, heparin, enoxaparin, desmopressin) & inducing bradycardia.